Loading...
XHKG
2216
Market cap53mUSD
Jul 09, Last price  
0.79HKD
1D
0.00%
1Q
-42.34%
IPO
-94.63%
Name

Broncus Holding Corp

Chart & Performance

D1W1MN
XHKG:2216 chart
P/E
P/S
305.12
EPS
Div Yield, %
Shrs. gr., 5y
16.45%
Rev. gr., 5y
-44.35%
Revenues
174k
-97.86%
8,072,0003,259,00010,891,0009,413,00010,255,0008,131,000174,000
Net income
-18m
L+16.81%
-32,551,000-48,237,000-236,178,000-28,036,000-28,091,000-15,303,000-17,875,000
CFO
-10m
L+0.01%
-15,815,000-15,588,000-31,494,000-30,954,000-26,132,000-10,002,000-10,002,775

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Broncus Holding Corporation is a global medical technology company specializing in the development of interventional pulmonology products. Its market reach extends across Mainland China, the European Union, the United States, and other international territories. The company's innovative product lineup includes advanced navigation systems such as LungPoint Virtual Bronchoscopic Navigation, a sophisticated computer-assisted image-based software solution. It also offers LungPoint Plus, a system providing real-time airway guidance crucial for lung biopsies and other medical interventions, and LungPro, a virtual bronchoscopic navigation product that enables three-dimensional real-time guided transbronchial needle aspiration alongside proprietary parenchymal navigation. Beyond navigation, Broncus provides a suite of therapeutic products. These feature InterVapor, a targeted bronchoscopic thermal vapor ablation system designed to treat diseased, hyper-inflated lung segments. Additionally, it offers an RF Generator paired with an RF Ablation Catheter, forming a radiofrequency ablation system specifically developed to target lung cancer. The H-Marker, a pulmonary surgical marker, is another key offering. The company further supplies a range of specialized procedural devices, including the BioStarNeedle, a single-use ultrasound-guided aspiration needle for retrieving tissue samples, and the FleXNeedle, a versatile multipurpose biopsy needle. Complementing these are various bronchoscopic accessories like the Archimedes Sheath, a sterile, single-use flexible tube that serves as a working channel during bronchoscopic procedures. The Archimedes Dilation Balloon, another sterile, single-use flexible tube with a distal balloon, is used to dilate target lung tissue within the bronchial tree after insertion through a bronchoscope or sheath. Finally, the Steerable Sheath provides a steerable adjustment handle and an additional working channel. Broncus Holding Corporation was established in 2012 and maintains its corporate headquarters in Hangzhou, China.
IPO date
Sep 24, 2021
Employees
314
Domiciled in
CN
Incorporated in
KY

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT